Literature DB >> 11952826

Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterisation of the lesion.

N L Diaz1, O Zerpa, L V Ponce, J Convit, A J Rondon, F J Tapia.   

Abstract

The American cutaneous forms of leishmaniasis include immune-responder individuals with localised cutaneous leishmaniasis (LCL) and non-responder individuals with diffuse cutaneous leishmaniasis (DCL). Patients with intermediate or chronic cutaneous leishmaniasis (ICL) have increased morbidity due to the length of their illness, atypical forms and areas of compromise. In the present study, we evaluated the expression of the leukocyte antigens (CD4, CD8, CLA: cutaneous lymphocyte antigen, CD69, CD83 and CD1a) and cytokines (IFN-gamma, IL-4, IL-10 and TGF-beta 1) in the lesions of patients with ICL (n = 18) using an immunocytochemical procedure. ICL results were compared with the information for LCL (n = 19) and DCL (n = 4). The numbers of CD4+ and CD8+ T cells in ICL were similar to those of LCL lesions, but significantly different (P < or = 0.05) from DCL lesions. LCL lesions have about half the numbers of early activated CD69+ cells as ICL, but most are CLA+ skin homing memory T cells, whereas ICL lesions have the highest number of CD69+ T cells, but about one-third of these cells expressed CLA. This suggests that the granuloma of ICL patients contains many activated T cells that are unprimed to cutaneous-launched antigens, thus contributing to an aberrant immune response. In contrast, DCL granulomas presented the lowest numbers of activated CD69+ and CLA+ cells, associated with the characteristic tolerogenic state of these patients. The immunolocalisation of cytokines showed a mixed cytokine pattern in ICL lesions with many positive cells for IL-10, TGF-beta 1, IL-4 and IFN-gamma, with a preponderance of the first two, and different from the prevalent Th1 and Th2 responses associated with LCL and DCL lesions, respectively. CD1a+ Langerhans cells were decreased (P < or = 0.05) in both ICL (271 +/- 15 cells/mm2) and DCL (245 +/- 19 cells/mm2) as compared to LCL (527 +/- 54 cells/mm2) epidermis. The percentage of IL-10+ epidermal Langerhans cells in ICL (33.69), from the total CD1a+ population, was higher than in LCL (17.45). In addition, fewer CD83+ primed Langerhans cells were present in ICL epidermis. The diminished participation of epidermal Langerhans cells, causing a defective signalling by the epidermis, in ICL lesions may account for the tissue-damaging state observed in these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11952826     DOI: 10.1034/j.1600-0625.2002.110104.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  19 in total

1.  Effector memory CD4(+) T cells differentially express activation associated molecules depending on the duration of American cutaneous leishmaniasis lesions.

Authors:  C de Oliveira Mendes-Aguiar; R Vieira-Gonçalves; L H Guimarães; M P de Oliveira-Neto; E M Carvalho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2016-06-06       Impact factor: 4.330

2.  The skin homing receptor cutaneous leucocyte-associated antigen (CLA) is up-regulated by Leishmania antigens in T lymphocytes during active cutaneous leishmaniasis.

Authors:  C de O Mendes-Aguiar; A Gomes-Silva; E Nunes; R Pereira-Carvalho; R S Nogueira; M de P Oliveira-Neto; A L Bertho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

3.  Transcriptomic landscape of skin lesions in cutaneous leishmaniasis reveals a strong CD8+ T cell immunosenescence signature linked to immunopathology.

Authors:  Carlos Henrique Fantecelle; Luciana Polaco Covre; Renan Garcia de Moura; Herbert Leonel de Matos Guedes; Camila Farias Amorim; Phillip Scott; David Mosser; Aloisio Falqueto; Arne N Akbar; Daniel Claudio Oliveira Gomes
Journal:  Immunology       Date:  2021-09-01       Impact factor: 7.397

Review 4.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

Review 5.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 6.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

Review 7.  Leishmania RNA virus: when the host pays the toll.

Authors:  Mary-Anne Hartley; Catherine Ronet; Haroun Zangger; Stephen M Beverley; Nicolas Fasel
Journal:  Front Cell Infect Microbiol       Date:  2012-07-12       Impact factor: 5.293

8.  Interleukin-10 and Transforming Growth Factor-β in Early and Late Lesions of Patients with Leishmania major induced Cutaneous Leishmaniasis.

Authors:  Sh Hejazi; Sg Hoseini; Sh Javanmard; Sh Zarkesh; A Khamesipour
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

9.  Interleukin-10 and Transforming Growth Factor-β in Early and Late Lesions of Patients with Leishmania major Induced Cutaneous Leishmaniasis.

Authors:  Sh Hejazi; Sg Hoseini; Sh Javanmard; Sh Zarkesh; A Khamesipour
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

10.  miR-548d-3p Alters Parasite Growth and Inflammation in Leishmania (Viannia) braziliensis Infection.

Authors:  Marina de Assis Souza; Eduardo Milton Ramos-Sanchez; Sandra Márcia Muxel; Dimitris Lagos; Luiza Campos Reis; Valéria Rêgo Alves Pereira; Maria Edileuza Felinto Brito; Ricardo Andrade Zampieri; Paul Martin Kaye; Lucile Maria Floeter-Winter; Hiro Goto
Journal:  Front Cell Infect Microbiol       Date:  2021-06-10       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.